

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

MAERTENS, et al.

Atty. Ref.: 2551-142

Serial No. Div of Serial No. 09/899,082

Group: Unassigned

Filed: April 12, 2004

Examiner: Unassigned

For: PROCESS FOR TYPING OF HCV ISOLATES

\* \* \* \* \*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

April 13, 2004

Sir:

**INFORMATION DISCLOSURE STATEMENT**

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**  
[within 3 months of filing or prior to 1st Office Action on the merits]  
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)]  
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)]  
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**  
[after Final Office Action or Allowance (requires Rule 97(e)  
Statement and Rule 17(p) fee), but before final fee payment]  
\$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith. Copies of the cited documents are not believed to be required as the same are of record in the parent Application Serial No. 09/899,082. The Examiner is requested to advise the undersigned however if further copies of the cited documents are required.

This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information

MAERTENS, et al.


Serial No. Div of Serial No. 09/899,082

contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,  
NIXON & VANDERHYE P.C.

By: \_\_\_\_\_



B. J. Sadoff

Reg. No. 36,663

1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

MAERTENS, et al.  
Serial No. Div of Serial No. 09/899,082

Sheet 1 of 2

**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.

DIVISIONAL OF SERIAL NO.

2551-142

09/899,082

APPLICANT

MAERTENS, et al.

(Use several sheets if necessary)

FILING DATE

GROUP

April 13, 2004

Unassigned

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,846,704	12/1998	Maertens et al			
	5,871,903	2/1999	Miyamura et al			
	5,372,928	12/1994	Miyamura et al			
	5,527,669	6/1996	Resnick et al			
	5,043,272	12/1998	Hartley			
	5,846,704 B1	12/1998	Maertens et al			
	6,171,784 B1	1/2001	Maertens et al			
	6,051,696 B1	4/2000	Maertens et al			
	6,548,244	4/2003	Maertens et al			
	5,527,669 A	6/1996	Resnick et al			
	6,297,370 B1	10/2001	Cha et al			
	5,620,852 A	4/1997	Lin et al			
	5,629,158	5/1997	Uhlen et al			
	6,495,670	12/2002	Maertens et al			

**FOREIGN PATENT DOCUMENTS**

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
WO 92/19743	11/1992	PCT				
WO 92/02642	2/1992	PCT				
529493 A2	3/1993	EP				
WO 93/23569	11/1993	PCT				
WO 92/10588	6/1992	WIPO				
EP 531974A	12/1999	EPO				

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

	Simmonds et al, J. of General Virology 74: 661-668 (1993)
	Chan et al, J. of General Virology 73: 1131-1141 (1992)
	Okamoto et al, J. of General Virology 7: 2697-2704 (1991)
	Ogata et al, PNAS (USA) 88: 3392-3396 (1991)
	Enomoto et al, Biochemical Biophysical Research Communications 170(3): 121-1025 (1990)
	Choo et al, PNAS (USA) 88: 2451-2455 (1991)
*Examiner	Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

MAERTENS, et al.  
Serial No. Div of Serial No. 09/899,082

Sheet 2 of 2

**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

2551-142

Div of Serial No. 09/899,082

APPLICANT

MAERTENS, et al.

(Use several sheets if necessary)

FILING DATE

GROUP

April 13, 2004

Unassigned

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,077,193	12/1991	Mishiro et al.			
	5,173,994	12/1992	Mishiro et al.			
	5,252,743	10/1993	Barrett et al.			
	5,427,909	6/995	Okamoto et al.			
	5,428,145	6/1995	Okamoto et al.			
	5,550,016	8/1996	Okamoto et al.			
	5,629,153	6/1997	Uhlen et al.			
	6,051,696	4/2000	Maertens et al.			
	6,190,864	2/2001	Cha et al.			

**FOREIGN PATENT DOCUMENTS**

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
0461863	12/1991	EP			
0469348	2/1992	EP			

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

Sommer et al. Nucleic Acids Research 17 (16):6749 (1989).
Takamizawa et al., J. of Virology 65 (3):1105-1113 (Mar. 1991).
Okamoto et al., Japanese J. of Experimental Medicine 60: 167-177 (1990).
Bukh et al., PNAS 89:4942-4946 (1992).
Okamoto et al., Virology 188:331-341 (1992).
Cha et al., PNAS 89:7144-7148 (1992).
Inchaupse et al., Hepatology 14: 595-600 (1991).
Weiner et al., Lancet 335: 1-3 (1990).
Lee et al., J. of Clinical Microbiology 30 : 1602-1604 (1992).
Cha et al., J. of Clinical Microbiology 29(11):2528-2534 (1991).
Hu et al., J. Clin. Invest. 89, 2040-2045 (1992)
Nakao et al., J. of General Virology 72: 2105-2112 (1991).
Nedjar (1991) J. Virological Methods 35, 297-304.
Okamoto et al. (1992) J. Gen. Virol. 73:673-79
Castillo et al. (1992) Journal of Virological Methods, Vol. 38, No. 1, pp 71-79
Martell et al., J. of Virology 66(5): 3225-3229 (May 1992)
Stratagene Catalog, pg 39 (1988)

*Examiner	Date Considered
-----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)